Na ʻIkepili Peptide 
Mei 1, 2025
ʻO nā ʻatikala a me nā ʻike huahana i hāʻawi ʻia ma kēia pūnaewele pūnaewele wale nō no ka hoʻolaha ʻana i ka ʻike a me nā kumu hoʻonaʻauao.
ʻO nā huahana i hāʻawi ʻia ma kēia pūnaewele i manaʻo wale ʻia no ka noiʻi in vitro. Hana ʻia ka noiʻi in vitro (Latin: *i ke aniani*, ʻo ia hoʻi i ka ipu aniani) ma waho o ke kino kanaka. ʻAʻole kēia mau huahana he lāʻau lapaʻau, ʻaʻole i ʻae ʻia e ka US Food and Drug Administration (FDA), a ʻaʻole pono e hoʻohana ʻia no ka pale ʻana, mālama, a hoʻōla paha i kekahi maʻi olakino, maʻi, a i ʻole maʻi. Ua pāpā loa ʻia e ke kānāwai ke hoʻokomo i kēia mau huahana i loko o ke kino kanaka a holoholona paha ma kekahi ʻano.
Polypeptide Purity Control and Verification Technical System
Hāʻawi ʻo Cocerpeptides.com i nā peptides me ka maʻemaʻe ma mua o 99%. Loaʻa i ka Cocer Peptides ka mana pololei a me ka hōʻoia ʻepekema o ka maʻemaʻe polypeptide ma o ka hoʻohui ʻana i nā ʻenehana holomua a me kahi ʻōnaehana hoʻokele maikaʻi piha: Ma ke kahua synthesis, hoʻohana ʻia ka automated solid-phase peptide synthesis (SPPS) e hōʻuluʻulu pololei i nā kaʻina amino acid. Hoʻohana ʻia kahi hoʻolālā hoʻomaʻemaʻe gradient mai ka medium-pressure liquid chromatography (MPLC) a hiki i ka preparative high-performance liquid chromatography (Prep-HPLC) i hoʻohana ʻia, e hoʻohana pono ana i ka haku mele ʻana a me nā kūlana elution e pili ana i nā waiwai physicochemical o ka peptide i hoʻopaʻa ʻia (hydrophobicity, hoʻoili uku, a me nā mea ʻē aʻe) e wehe pono i nā haumia. No ka ʻike maʻemaʻe, ʻo ka reverse-phase high-performance liquid chromatography (RP-HPLC) ke ʻano kumu, e hoʻokaʻawale ana i nā ʻāpana ma o ka hoʻokaʻawale ʻana o nā molekole ma waena o ka pae paʻa (hydrophobic packing) a me ka pae kelepona (polar solvent). Hoʻoholo ʻia ka maʻemaʻe ma o ka hoʻopaʻa ʻana i ka manawa kūpono a me ka hoʻomaʻamaʻa wahi kiʻekiʻe. I kēia manawa, hui pū ʻia ka electrospray ionization mass spectrometry (ESI-MS) e hōʻoia pololei i ke kaumaha molekala a me ka hoʻohui ʻana ma o ka nānā ʻana i ka ratio mass-to-charge (m/z), e hoʻopau ana i nā haumia heterogeneous structurally. Hoʻopili ka hoʻokele maikaʻi i ke kaulahao holoʻokoʻa mai ka ʻae ʻana i nā mea maka, ka nānā ʻana i ke kaʻina hana synthesis a hiki i ka hoʻokuʻu ʻana i ka huahana. Kūkulu ʻia kahi manamana lima maikaʻi mau me ka hoʻohana ʻana i nā hōʻailona multi-dimensional (HPLC pure, MS molecular weight, solvent residue, etc.), a loaʻa ka traceability data batch ma o ka ʻōnaehana hoʻokele ʻikepili (LIMS), e hōʻoia ana i kēlā me kēia pūʻulu e hoʻokō i nā kūlana maʻemaʻe i koho mua ʻia. Hāʻawi kēia ʻōnaehana i kahi hōʻoia ʻenehana hilinaʻi no ka hoʻomākaukau ʻana i nā polypeptides maʻemaʻe kiʻekiʻe ma o ka hoʻohui ʻana o nā kaʻina hana, ka ʻike multi-dimensional, a me ke kaʻina hana piha.
Nā Manaʻo o ka High-Performance Liquid Chromatography (HPLC) a me Mass Spectrometry (MS)
High-performance liquid chromatography (HPLC) kahi ʻenehana hoʻokaʻawale i hoʻohana nui ʻia e Cocer Peptides no ka hoʻomaʻemaʻe peptide. Ke alakaʻi ʻia nei e ka pauma paʻa kiʻekiʻe, lawe ka pae kelepona i nā laʻana ma o ke kolamu chromatographic i hoʻopaʻa ʻia me kahi pae paʻa kikoʻī, e loaʻa ana ka hoʻokaʻawale ʻana ma muli o nā ʻokoʻa o ka hoʻokaʻawale ʻana o nā ʻāpana ma waena o nā pae ʻelua. Hōʻike ia i ka hana hoʻokaʻawale kiʻekiʻe, ka wikiwiki o ka nānā ʻana, a me ka naʻau ʻike ikaika, e hiki ai ke hopu pololei i nā ʻokoʻa maʻalahi ma waena o nā peptides a me nā haumia e like me ka sequence analogs a me ka holoi ʻana i nā peptides.
ʻO ka mass spectrometry (MS) kahi ʻano analytical e hoʻohuli ai i nā molekole peptide i loko o nā ion o ke kinoea ma o ka ʻenehana ionization a hoʻokaʻawale / ʻike i nā ion ma muli o kā lākou mass-to-charge ratio (m/z). Hiki iā ia ke hoʻoholo pololei i ke kaumaha o nā peptides a hoʻokaʻawale i nā kaʻina amino acid ma o ka ʻikepili ion fragment, e lawelawe ana ma ke ʻano he ʻenehana koʻikoʻi no ka hōʻoia ʻana i ka pololei o ka peptide. ʻO ka hui pū ʻana o kēia mau ʻenehana ʻelua e hiki ai iā Cocer Peptides ke hoʻokumu i kahi ʻōnaehana hoʻokele maikaʻi piha mai ka hoʻokaʻawale maʻemaʻe a me nā hiʻohiʻona hoʻopaʻa hoʻonohonoho. ʻO nā ʻano hana ʻelua nā ʻenehana ʻike peptide kiʻekiʻe e hōʻike ʻepekema i ka maʻemaʻe a me ka haku ʻana o nā peptides i kauoha ʻia mai cocerpeptides.com.
Ua kūpaʻa ʻo Cocer Peptides i ka unuhi ʻana i nā ʻenehana analytical ʻokiʻoki i loko o ka hōʻoia ʻana o ka maikaʻi. Hoʻolako ʻia kā mākou peptide synthesis laboratories me nā spectrometers nui kiʻekiʻe a me nā ʻōnaehana chromatography wai ultra-high-performance. Ma o ka ʻike ʻana i ka manawa maoli a me ka hoʻohālikelike ʻikepili o nā laʻana i kēlā me kēia pae hana, hoʻomau mākou i nā kaʻina hana synthesis e hōʻoia i ka hāʻawi ʻia ʻana o kēlā me kēia huahana peptide i nā mea kūʻai aku me ka maʻemaʻe ʻokoʻa.
Manaʻo ʻia nā pae maʻemaʻe peptide
Hāʻawi ʻo Cocer Peptides i nā peptides maʻemaʻe kiʻekiʻe loa (ka maʻemaʻe ≥99%) no ka noiʻi a me ka hoʻomohala ʻana. ʻO ka pae maʻemaʻe peptide haʻahaʻa i ʻōlelo ʻia no nā noi kikoʻī e pili ana i ka noi:
• Ma ka noiʻi biochemical, ʻo nā peptides i hoʻohana ʻia no ka nānā ʻana i ka hana enzyme e koi maʻamau i ka ≥85% maʻemaʻe.
• I ka hoʻomohala ʻana i ka lāʻau lapaʻau, pono e hoʻokō nā peptides no nā hoʻokolohua preclinical> 98% maʻemaʻe kiʻekiʻe e hōʻoia i ka hana olaola a me ka palekana.
• No nā noi diagnostic (e laʻa, antigen peptides i immunoassays), ʻo ka maʻemaʻe i ʻōlelo ʻia he 90% -95% e hōʻoiaʻiʻo i ka ʻike kikoʻī a me ka ʻike.
Ke hilinaʻi nei ʻo Cocer Peptides i ka maikaʻi o kā mākou huahana āpau, e hoʻokō ana i ka nānā ʻana i ka maikaʻi ma kēlā me kēia pae o ka peptide synthesis—mai ka hoʻomaʻemaʻe peptide crude a hiki i ka hoʻokuʻu ʻana i ka huahana hope. Ma o nā kaʻina hana hoʻomaʻemaʻe a me ka hōʻoia ʻana, hōʻoia mākou i kēlā me kēia pūʻulu e hoʻokō a ʻoi aku paha i nā koi maʻemaʻe no nā noi kikoʻī. Eia nā laʻana o nā pae maʻemaʻe liʻiliʻi e ʻae ʻia:
Maʻemaʻe Kiʻekiʻe (>95%)
• Ka noiʻi a me ka hana ʻana i ka lāʻau lapaʻau Polypeptide
• Hoʻomākaukau i nā lāʻau lapaʻau i manaʻo ʻia
• Nā mea maka no nā mea hoʻopaʻa hoʻopaʻa ola (e laʻa, ELISA, pahu immunoassay)
• Hoʻomohala ʻana i nā lāʻau lapaʻau polypeptide
• Ka hoʻomākaukau ʻana i nā peptides e ʻimi ana no nā conjugates antibody-drug (ADCs)
• Nā mea hoʻopaʻa polypeptide no ka noiʻi ʻepekema ola (e laʻa, nā agonists / antagonists)
• Ka noiʻi e pili ana i ka huli ʻana i ka hoʻololi peptide no nā vectors gene therapy
• Hoʻomohala ʻana i nā antibiotics polypeptide / antimicrobial peptides
• Hoʻomākaukau i nā mea hoʻohālikelike hormone polypeptide (e laʻa, nā analog insulin)
• Nā kūlana kuhikuhi no ka ʻike biomarker
• Ka noiʻi ʻana i nā mea hoʻohui moʻomeheu cell
• Nā peptides synthetic no ka nānā ʻana i ka hoʻolālā ʻana o ka protein a me nā haʻawina hana
Maʻemaʻe haʻahaʻa (>85%)
• Ka nānā 'ana i ka hana mua ma ka noi'i lā'au polypeptide
• Nā mea hoʻohui peptide no nā enzyme ʻoihana
• hōʻailona peptide maka mea
• Hoʻololi i ka ʻili o nā mea biomaterial (e laʻa, nā catheters lapaʻau, nā scaffolds ʻenekinia kiko)
• Hoʻomākaukau i nā peptides antimicrobial mahiʻai
• Ka noiʻi hoʻopili pūnaewele
• Nā mea maka no ka polypeptide surfactants/detergents
• Polypeptide reagents no ka noiʻi mechanistic mua i nā haʻawina ʻepekema
Maʻemaʻe Haʻahaʻa (>70%)
• Nā haʻawina mua o ka hoʻolālā-hana (SAR).
• ʻO ka hōʻoia mua o ka hoʻopaʻa ʻana i ka protein
• Ka nānā 'ana i ka cytotoxicity
• Kiʻekiʻe-throughput kānana o polypeptide lāʻau kepau pūhui
He kūpono nā polypeptides maʻemaʻe kiʻekiʻe no nā hiʻohiʻona e koi ana i ka maʻemaʻe paʻa. ʻO nā peptides ultra-high-purity i hāʻawi ʻia e Cocer Peptides hiki ke hoʻokō a ʻoi aku ma mua o nā kūlana maʻemaʻe a pau.
